详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

A Novel Signature of Lipid Metabolism-Related Gene Predicts Prognosis and Response to Immunotherapy in Lung Adenocarcinoma.

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 预警期刊

作者：

机构： [1]Shanghai Tongren Hospital and Faculty of Public Health, Hongqiao International Institute of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China, [2]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China, [3]Shanghai Hospital Development Center, Shanghai, China

出处：

DOI：

ISSN：

关键词： lipid metabolism lung adenocarcinoma tumor microenvironment immunotherapy prognosis model immune checkpoint

摘要：

Background: Lipid metabolism disorder, a new hallmark of cancer initiation, has been involved in lung adenocarcinoma (LUAD). However, few biomarkers about lipid metabolism-related genes (LMRGs) have been developed for prognosis prediction and clinical treatment of LUAD patients. Methods: In this study, we constructed and validated an effective prognostic prediction model for LUAD patients depending on LMRGs. Subsequently, we investigated the prediction model from immune microenvironment, genomic changes, and immunotherapy. Results: Then, eleven LMRGs were identified and applied to LUAD subtyping. In comparison with the high-risk group, the low-risk group exhibited a remarkably favorable prognosis, along with a higher immune score and lower tumor purity. Moreover, the low-risk group presented higher levels of immune checkpoint molecules, lower tumor immune dysfunction and exclusion (TIDE) score and tumor mutation burden (TMB), and higher likelihood of benefiting from immunotherapy. Furthermore, the genomic changes of six LMRGs (CD79A, HACD1, CYP17A1, SLCO1B3, ANGPTL4, and LDHA) were responsible for the difference in susceptibility to LUAD by greatly influencing B-cell activation. Conclusion: Generally speaking, the LMRG model is a reliable independent biomarker for predicting adverse outcomes in LUAD patients and has the potential to facilitate risk-stratified immunotherapy.Copyright © 2022 Zhang, Qian, Quan, Zhu and Qian.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区生物学

小类 | 2 区发育生物学 3 区细胞生物学

最新[2023]版：

大类 | 2 区生物学

小类 | 2 区发育生物学 3 区细胞生物学

第一作者：

第一作者机构： [1]Shanghai Tongren Hospital and Faculty of Public Health, Hongqiao International Institute of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China,

通讯作者：

通讯机构： [2]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China, [3]Shanghai Hospital Development Center, Shanghai, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]A Novel Signature of Lipid Metabolism-Related Gene Predicts Prognosis and Response to Immunotherapy in Lung Adenocarcinoma [2]The influence of microenvironment on tumor immunotherapy [3]Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy [4]Biomarkers for predicting the efficacy of immune checkpoint inhibitors [5]Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade [6]Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma [7]Biomineralized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy [8]免疫检查点抑制剂在儿童恶性肿瘤治疗中的研究进展 [9]Functions of Immune Checkpoint Molecules Beyond Immune Evasion [10]Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy